Immunic, Inc. reported progress in its late-stage development of vidofludimus calcium for multiple sclerosis (MS), with Phase 3 ENSURE trials for relapsing MS on track to deliver top-line data by the end of 2026. The company also plans to start a Phase 3 trial for progressive MS later this year. Leadership expansions include new CEO Erik Lundgren and Chief Medical Officer Michael Panzara, bringing expertise to support clinical development and commercialization. Financially, Immunic is well-capitalized following a private placement and expects to fund operations into late 2027, positioning the company for potential regulatory submissions and commercial launch if trials succeed.
Tractor Supply's CEO, Lawton, purchased 15,600 shares of the company for $501,540 despite the stock having declined 44%. This insider buying signals confidence in the company's future prospects even as the stock price has fallen significantly. Such m...
Hyperscale Data's Board is reviewing strategic options, including a potential sale or partnership, to maximize shareholder value from its Michigan AI data center. The center has secured contracts worth over $1.2 billion for 20 MW capacity, with poten...
Carolina Rush Corporation secured nine new mineral leases totaling 2,524 acres adjacent to its Brewer Gold-Copper Project in South Carolina, expanding its Jefferson Project to a contiguous 3,480-acre land package. Most leases require no annual paymen...
BioHarvest Sciences announced its first contract development and manufacturing organization (CDMO) agreement to produce 20 tons of a rare botanical fragrance over two years, expected to boost profitable growth. The fragrance ingredient is highly valu...
Japan Gold Corp. completed a 21.3 km geophysical survey at its Mizobe Project in Kyushu, Japan, enhancing the geological model of the area. This survey integrated with previous data to better understand structures and potential gold pathways beneath ...
